Drugs / Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)
Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02677350 | Dec 2019 → Dec 2025 | perianal Crohn disease | Joshua M Hare | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02677350 ↗ |
| Modality | Cell therapy | “allogeneic mesenchymal stem cells” NCT02677350 ↗ |
| Route | Other | “Peri-fistula injections” NCT02677350 ↗ |